Metabolomic Biomarkers Evaluation in Pulmonary Fibrosis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

59 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-05-05

Study Completion Date

2025-01-18

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Pulmonary fibrosis (PF) are a heterogeneous group of interstitial lung diseases who may have a progressive phenotype often associated with loss of lung function, chronic respiratory symptoms, quality of life limitation as well significant morbidity and mortality. The identification of reliable biomarkers able to help in early diagnosis and predict disease progression are crucial for improving patient life. Although many biomarkers have been proposed, there is no consensus on reliable markers for IPF. Alterations in fatty acid (FA) metabolism have drawn increasing attention in the IPF pathogenesis, but there is no consensus on the specific FA changes. Alterations in FA composition have been shown to promote pro-fibrotic traits in epithelial cells, fibroblasts, and myofibroblasts. However, while specific fatty acid (FA) alterations have been identified in the serum of IPF patients, no consensus exists on the exact changes for individual FAs

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Genomic and Proteomic Analysis of Disease Progression in Idiopathic Pulmonary Fibrosis (IPF)

NCT00373841

Idiopathic Pulmonary Fibrosis

RECRUITING

Optimising Screening for Early Disease Detection in Familial Pulmonary Fibrosis

NCT05367349

Pulmonary Fibrosis Idiopathic Familial

UNKNOWN

Biomarker Discovery for Novel Drug Development in Idiopathic Pulmonary Fibrosis

NCT01718990

Idiopathic Pulmonary Fibrosis (IPF)

COMPLETED

Clinical Genetics and Screening for Idiopathic Pulmonary Fibrosis

NCT06521125

Familial Pulmonary Fibrosis Idiopathic Pulmonary Fibrosis

NOT_YET_RECRUITING

Cardiovascular Fibrosis in Idiopathic Pulmonary Fibrosis

NCT04177251

Idiopathic Pulmonary Fibrosis Cardiac Fibrosis Arterial Fibrosis

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pulmonary Fibrosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Pulmonary Fibrosis patients

Fatty acids measurement

Intervention Type DIAGNOSTIC_TEST

Serum analysis for metabolomic biomarker identification

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Fatty acids measurement

Serum analysis for metabolomic biomarker identification

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Confirmed IPF diagnosis based on the 2018 ATS/ERS/JRS/ALAT guidelines \[PMID: 30168753\] or other fibrotising ILDs within the past five years,
* Age ≥ 40 years, 3) ability to provide informed consent.

Exclusion Criteria

* A current diagnosis of asthma or chronic obstructive pulmonary disease (COPD), 2) an acute PF exacerbation within the past three months.
* Use of medications who may alter metabolomic biomarkers, ex. statins.

Minimum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes